EC Number   |
Application |
Reference |
|---|
   3.4.16.2 | analysis |
enzymatic sequencing by MALDI-MS combined with carboxypeptidase cleavage |
683809 |
| 3.4.16.2 | medicine |
an inhibitor of activated TAFI might be used as a therapeutic agent in venous thrombotic diseases |
683829 |
| 3.4.16.2 | medicine |
analysis of prolyl carboxypeptidase activity in serum of 50 stroke patients at admission, and at 24 h, 72 h and 7 days after stroke onset. The decrease in prolyl carboxypeptidase levels in the first 24 h after stroke onset is associated with stroke severity and an unfavourable short-term stroke outcome. High National Institutes of Health Stroke scale scores and infarct volumes at admission are related with a more pronounced decrease of prolyl carboxypeptidase in the first 24 h after stroke |
732574 |
| 3.4.16.2 | medicine |
E112D could be a highly sensitive and specific early predictor of preeclampsia among woman with chronic hypertension |
683041 |
| 3.4.16.2 | medicine |
E112D polymorphism in the PRCP gene may be a useful genetic marker to predict the antihypertensive effect of short-term benazepril treatment in hypertensive patients of Anhui Province, China |
708136 |
| 3.4.16.2 | medicine |
prolyl carboxypeptidase and prolyl endopeptidase regulate insulin receptor substrate IRS-1 stability and PI3K/AKT activation in pancreatic cancer |
732142 |
| 3.4.16.2 | medicine |
the results could provide new therapeutic opportunity for the treatment of infection |
683125 |
| 3.4.16.2 | medicine |
the validity of prolylcarboxypeptidase as a site specific therapeutic that could mitigate inflammatory injury is discussed |
683552 |
